Back to search
FDAFDA · Food and drugs·Recall number D-0468-2017

Olanzapine tablets, USP, 2.5 mg, packaged in a 30-count bottle, Rx only, Mfd: By: Dr. Reddy's Laboratories Limited, Bachupally, India, NDC 55111-163-30

Published February 15, 2017 · Recall initiated: October 13, 2016

Summary

FDA records drug Class III recall D-0468-2017, published February 15, 2017 and initiated October 13, 2016. Recalling firm: Dr. Reddy's Laboratories, Inc.; Status: Terminated; Reported quantity: 5,904 bottles; Lot: C500202. Class III means the product is not likely to cause adverse health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Failed impurities/degradation specifications: due to out-of-specification result for the Related Substance Compound C (Impurity 6 - N-Oxide at the 18 month stability station.

What to do

Voluntary: Firm initiated · Letter

Get an email if OLANZAPINE has another recall

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Brand
OLANZAPINE
Manufacturer
Dr. Reddy's Laboratories, Inc.
Distributor
US Nationwide
Lot
C500202
Risk classification
Class III
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Olanzapine tablets, USP, 2.5 mg, packaged in a 30-count bottle, Rx only, Mfd: By: Dr. Reddy's Laboratories Limited, Bachupally, India, NDC 55111-163-30 recalled?

Yes. FDA published recall D-0468-2017 on February 15, 2017. Reported hazard: Failed impurities/degradation specifications: due to out-of-specification result for the Related Substance Compound C (Impurity 6 - N-Oxide at the 18 month stability station.

What should I do if I have this product?

Voluntary: Firm initiated · Letter

How do I know if my unit is part of the recall?

Compare your product details with the notice. Brand: OLANZAPINE.